VIVUS Sees Significant Increase in Short Interest
Shares of VIVUS saw a significant increase in short interest during the month of January.
Trending on the Topix Network
Mon Apr 14, 2014
What Arena's Belviq Television Ad Campaign Means For The Stock
The weight loss drug Belviq from Arena Pharmaceuticals is now being promoted on television with a national advertising campaign .
Fri Apr 11, 2014
Is Orexigen Attractive Near 52-Week Lows?
Orexigen is trading just 10% above 52-week lows at just over $5 per share as the week closes out.
Avanafil Clinical Data to Be Presented at European Association of Urology
VIVUS today announced that a poster describing results of a clinical study examining onset of action of avanafil will be presented during the 29th Annual European Association of Urology Congress at StockholmsmA ssan in Stockholm, Sweden.
Thu Apr 10, 2014
Stocks to Watch Thursday: VIVUS, Inc., Zillow Inc, and ImmunoGen, Inc.
Interestingly, short-term call open interest has almost doubled since March 24, while put open interest climbed less than 1%.
Tue Apr 08, 2014
Three VIVUS Directors Not Standing for Re-Election
VIVUS, Inc. today announced that J. Martin Carroll, Mark B. Logan and Robert N. Wilson have decided not to stand for re-election when their terms expire at the Annual Meeting of Stockholders, to be held on June 20, 2014.
Fri Apr 04, 2014
Morning Market Losers
SGOCO Group shares declined 28.65% to $2.84 after the company reported reported preliminary Q4 earnings of $0.07 per share on revenue of $44.2 million.
Thu Apr 03, 2014
Why Vivus (VVUS) Stock Is Plunging Today
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.
VIVUS to Present at Upcoming Investor Conference
VIVUS, Inc. today announced that management will present an overview of the company at the following investor conference: VIVUS is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health.
The Motley Fool
Morning Movers in Biotech: Medicines Co., Omeros Corporation, Opko Health, Inc. and VIVUS, Inc.
Let's take a look at today's top stories in biotech and health care. Keep an eye out for The Medicines Company FDA accepts The Medicines Company's Biologic License Application for Fibrocaps The Medicines Company has announced that the U.S. Food and Drug Administration, or FDA, has accepted a biologic license application, or BLA, for its ... (more)
Analyst Downgrades: Amazon.com, Inc., Citigroup Inc, and VIVUS, Inc.
However, the reception was lukewarm, with AMZN ending the session lower at $341.96, and at least one brokerage firm waxing pessimistic on the $99 box that delivers streaming content to TVs.
VIVUS Rating Lowered to Underweight at Piper Jaffray
VVUS has been the subject of a number of other recent research reports. Analysts at WallachBeth Capital cut their price target on shares of VIVUS from $11.00 to $8.00 in a research note on Tuesday, February 25th.
Fri Mar 28, 2014
Arena - Scripts, Ads, Sales Reps
While the Arena equity may not have been too exciting of late, there are some interesting developments about to begin.
Wed Mar 26, 2014
Vivus: Shares Are Oversold, Pressure Is On To Secure A Commercial...
New management is focused on improving launch and finding a commercial partner to provide the necessary sales infrastructure while charting a path for EU approval and trimming expenses.
Tue Mar 25, 2014
AcelRx Pharmaceuticals Appoints Timothy E. Morris as Chief Financial Officer
Mr. Morris brings 30 years of professional finance and accounting experience to AcelRx, 18 of those years spent in the role of chief financial officer, most recently operating in this capacity at VIVUS, Inc., a commercial-stage biopharmaceutical company.
Mon Mar 24, 2014
Midday Market Stats: Dow Jones Industrial Average Down On Soft U.S. Factory Data
Now, however, the DJI is down 36.36 points, or 0.22%, at 16,266.41, following the release of the U.S. flash purchasing managers index for March , which dipped to a weaker-than-expected reading of 55.5 from a nearly four-month-high reading of 57.1 in February.
Fri Mar 21, 2014
The Motley Fool
Better Chance of Making a Comeback: Amarin plc or VIVUS, Inc.?
Amarin and VIVUS have both fallen on hard times. Which stock has the best chance to regain its former glory? I am a strong advocate of investing in so-called "comeback stories."
Wed Mar 19, 2014
Shari Belafonte Partners With VIVUS to Encourage Adults to Speak With ...
Ms. Belafonte, an actress, model, photographer, writer, singer and daughter of famed musician and actor Harry Belafonte, knows that the impact of being overweight is more than superficial.